Detalles de la búsqueda
1.
Qualitative and Psychometric Evaluation of PROMIS®-29 to Assess General Health-Related Quality of Life in Patients With Moderately to Severely Active Inflammatory Bowel Disease.
Value Health
; 2024 Jun 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38843977
2.
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis.
N Engl J Med
; 381(13): 1201-1214, 2019 09 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-31553833
3.
Ustekinumab Pharmacokinetics and Exposure Response in a Phase 3 Randomized Trial of Patients With Ulcerative Colitis.
Clin Gastroenterol Hepatol
; 18(10): 2244-2255.e9, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31816446
4.
Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.
N Engl J Med
; 375(20): 1946-1960, 2016 11 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-27959607
5.
Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease.
Gastroenterology
; 154(6): 1660-1671, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29409871
6.
Gene Expression Signature for Prediction of Golimumab Response in a Phase 2a Open-Label Trial of Patients With Ulcerative Colitis.
Gastroenterology
; 155(4): 1008-1011.e8, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-29981298
7.
Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease.
Gastroenterology
; 155(4): 1045-1058, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-29909019
8.
Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection.
Gastroenterology
; 150(7): 1568-1578, 2016 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-26946343
9.
Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid: A proof-of-concept study.
Hepatology
; 64(1): 189-99, 2016 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-26597786
10.
Ustekinumab induction and maintenance therapy in refractory Crohn's disease.
N Engl J Med
; 367(16): 1519-28, 2012 Oct 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-23075178
11.
Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.
Gastroenterology
; 146(1): 96-109.e1, 2014 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-23770005
12.
Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.
Gastroenterology
; 146(1): 85-95; quiz e14-5, 2014 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-23735746
13.
Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis.
Gastroenterology
; 147(6): 1296-1307.e5, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-25173754
14.
Endoscopic and clinical variables that predict sustained remission in children with ulcerative colitis treated with infliximab.
Clin Gastroenterol Hepatol
; 11(11): 1460-5, 2013 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-23672831
15.
Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial.
Lancet Gastroenterol Hepatol
; 8(4): 307-320, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36738762
16.
A Phase 2b, Randomised, Double-blind, Placebo-controlled, Parallel-arm, Multicenter Study Evaluating the Safety and Efficacy of Tesnatilimab in Patients with Moderately to Severely Active Crohn's Disease.
J Crohns Colitis
; 17(8): 1235-1251, 2023 Aug 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-36939629
17.
Qualitative and psychometric evaluation of the PROMIS®-Fatigue SF-7a scale to assess fatigue in patients with moderately to severely active inflammatory bowel disease.
J Patient Rep Outcomes
; 7(1): 115, 2023 Nov 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-37962770
18.
Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis.
Clin Gastroenterol Hepatol
; 10(4): 391-9.e1, 2012 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-22155755
19.
Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab.
Gastroenterology
; 137(4): 1250-60; quiz 1520, 2009 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-19596014
20.
IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease.
J Crohns Colitis
; 14(1): 23-32, 2020 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31158271